JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Science · 21.06.2024 · 384 (6702)
DOI: 10.1126/science.ade8520 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Science, erschienen am 21.06.2024. Verfasst von Jaroslav Zak und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Immune Checkpoint Inhibitors, Janus Kinase Inhibitors, Nitriles. Die Arbeit wurde bisher 214-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK inhibitor ruxolitinib with anti–PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of immune checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
- Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands.
- Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
- Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA.
- Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
ORCID-Profile: Jaroslav Zak, Isaraphorn Pratumchai, Reza Beheshti Zavareh, Luke L Lairson, Michael B A Oldstone, Judith A Varner, Qing Cao, Umar Farooq, Vaishalee P Kenkre, Veronika Bachanova, John R Teijaro
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- NCI NIH HHS
Zitieren
APA
Zak, J., Pratumchai, I., Marro, B. S., Marquardt, K. L., Zavareh, R. B., Lairson, L. L., Oldstone, M. B. A., Varner, J. A., Hegerova, L., Cao, Q., Farooq, U., Kenkre, V. P., Bachanova, V., & Teijaro, J. R. (2024). JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science, 384(6702). https://doi.org/10.1126/science.ade8520
Vancouver
Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science. 2024;384(6702). doi:10.1126/science.ade8520
BibTeX
@article{Zak2024,
author = {Zak, Jaroslav and Pratumchai, Isaraphorn and Marro, Brett S and Marquardt, Kristi L and Zavareh, Reza Beheshti and Lairson, Luke L and Oldstone, Michael B A and Varner, Judith A and Hegerova, Livia and Cao, Qing and Farooq, Umar and Kenkre, Vaishalee P and Bachanova, Veronika and Teijaro, John R},
title = {JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma},
journal = {Science},
year = {2024},
volume = {384},
number = {6702},
doi = {10.1126/science.ade8520}
}
EUVIMED